Albert J Fitzgibbons III
CIK 1043486 · last filed 2013-04-29
Albert J Fitzgibbons III is a corporate insider who has filed 11 SEC Form 4 insider transactions across 1 company since 2007. Across all open-market trades the lifetime net is +$420.0M, making them a net buyer over the disclosed history. 4 SEC filings were submitted jointly with John A. Bartholdson.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
OMPI price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
200 SOUTH MICHIGAN AVE
CHICAGO, IL 60604
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Obagi Medical Products, Inc. (OMPI) Delisted | Director | 5,685,238 | — | — | $420.00M | 8 | 2012-06-08 |
Recent Filings
11 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2013-04-29 | — | Disp (D) | −17,953 | -$430.9K | |
| 2012-06-08 | Obagi Medical Products, Inc. (OMPI) Delisted | Grant (A) | +2,206 | $0 | EDGAR |
| 2011-06-09 | Obagi Medical Products, Inc. (OMPI) Delisted | Grant (A) | +3,209 | $0 | EDGAR |
| 2010-12-01 | Obagi Medical Products, Inc. (OMPI) Delisted | Disp (D) | −2,688,668 | -$26.46M | EDGAR |
| 2010-06-10 | Obagi Medical Products, Inc. (OMPI) Delisted | Grant (A) | +2,463 | $0 | EDGAR |
| 2009-06-22 | Obagi Medical Products, Inc. (OMPI) Delisted | Grant (A) | +4,055 | $0 | EDGAR |
| 2008-06-12 | Obagi Medical Products, Inc. (OMPI) Delisted | Grant (A) | +3,457 | $0 | EDGAR |
| 2008-04-21 | — | Grant (A) | +4,156 | $0 | |
| 2007-10-19 | Obagi Medical Products, Inc. (OMPI) Delisted | Sell (S) | +21,000,000 | $420.00M | EDGAR |
| 2007-07-31 | — | Grant (A) | +4,869 | $0 |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.